Buchumschlag

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Wah Loong Chan, Kee Huat Chuah
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
von: Kee Huat Chuah, et al.
Veröffentlicht: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
von: Kee Huat Chuah, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Rong‐Xiang Ng, et al.
Veröffentlicht: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
von: Qiong Yi, et al.
Veröffentlicht: (2024)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
von: Eunice Yewon Lee, et al.
Veröffentlicht: (2024)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
von: Derek D. Satre, et al.
Veröffentlicht: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
von: Mathias Jachs, et al.
Veröffentlicht: (2025)

Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
von: Kee Huat Chuah, et al.
Veröffentlicht: (2024)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
von: Benedikt Simbrunner, et al.
Veröffentlicht: (2025)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
von: Yixuan Zhu, et al.
Veröffentlicht: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
von: Karen Cheuk‐Ying Ho, et al.
Veröffentlicht: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
von: Paul Y. Kwo, et al.
Veröffentlicht: (2026)

Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Juan Macias, et al.
Veröffentlicht: (2024)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
von: Kelly Torosian, et al.
Veröffentlicht: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
von: Amy Sangam, et al.
Veröffentlicht: (2024)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
von: Rosellina M. Mancina, et al.
Veröffentlicht: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
von: Ming Liu, et al.
Veröffentlicht: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Gian Paolo Caviglia, et al.
Veröffentlicht: (2025)

Editorial: Silent But Detectable—High‐Throughput Proteomics to Identify Clinically Significant Liver Disease
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
von: Terry Cheuk‐Fung Yip, et al.
Veröffentlicht: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
von: Seren Gedallovich, et al.
Veröffentlicht: (2024)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
von: Stine Johansen, et al.
Veröffentlicht: (2026)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
von: Glenn Jun Kit Ho, et al.
Veröffentlicht: (2025)

Risk Factors for Liver Disease Cluster Geographically: A Precision Public Health Analysis of a UK City
von: R. Parker, et al.
Veröffentlicht: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2025)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
von: C. C. Mark Cheah, et al.
Veröffentlicht: (2025)

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply
von: Mattias Mandorfer, et al.
Veröffentlicht: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
von: Xiao‐Dong Zhou, et al.
Veröffentlicht: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
von: Chunlong Liu, et al.
Veröffentlicht: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)